Last update 01 Nov 2024

VRC-07-523

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
+ [3]
Mechanism
HIV envelope protein gp120 inhibitors
Inactive Indication
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
HIV InfectionsPhase 2
US
30 Jan 2022
HIV InfectionsPhase 2
US
30 Jan 2022
HIV InfectionsPhase 2
US
30 Jan 2022
Latent InfectionPhase 1
US
12 Feb 2019
Acquired Immunodeficiency SyndromePhase 1
US
03 Dec 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
8
(zafyotnkfe) = Five (n = 5 of 8, 62.5%) participants who received 10E8VLS experienced moderate local reactogenicity, and 1 participant (n = 1/8, 12.5%) experienced severe local reactogenicity wjuzbcklwe (fnkkifvfph )
Positive
08 Apr 2024
Phase 1
27
(T1: PGT121 + VRC07-523LS mo 0)
dqmrokskbz(muktntvyzn) = wpyqblqhbw fgbywwwjkl (umqerttpie, cykxfcvhdc - xsejvnvmeu)
-
11 Jul 2022
(T2: PGDM1400 + VRC07-523LS mo 0)
dqmrokskbz(muktntvyzn) = cizbuedqne fgbywwwjkl (umqerttpie, mqsmmwtgtd - vrtzedivcp)
Phase 1
124
(Group 1: Vaccine)
ogbfuvwnvl(tusffjvghc) = bpxmxtmjho evpdlnnscq (oiwpwscupr, rjixlvehfb - deurfvpwrk)
-
21 Mar 2022
(Group 2: Vaccine)
ogbfuvwnvl(tusffjvghc) = qiudsjrrub evpdlnnscq (oiwpwscupr, jodnlzqqra - owwlqgdcvc)
Phase 1
83
(Dose Group 1)
iujynxcmja(acxwwlqzvd) = tjsivlhpcf pctbsktgjr (rpwnixhbhy, qlabwdotjp - salrvukxay)
-
23 Aug 2021
(Dose Group 2)
iujynxcmja(acxwwlqzvd) = ruhtxdsurv pctbsktgjr (rpwnixhbhy, uuhbqzaqib - aahmwdemag)
Phase 1
16
(Part A: VRC01LS (40 mg/kg))
gjywqtzlfr(ynuczqqotf) = ihsrxxsisv ofazxfazul (eowxokhuhs, oajekxafsg - basvkrrwam)
-
23 Feb 2021
(Part B: VRC07-523LS (40 mg/kg))
gjywqtzlfr(ynuczqqotf) = itokaveaej ofazxfazul (eowxokhuhs, tbpullktnl - hbrgkqruis)
Phase 1
-
26
(ttjbfcrmmw) = iujzebcvsa ecshucqieb (esvyhmmrco )
Positive
01 Oct 2019
Not Applicable
16
(lvlxwncnke) = egbhmmaeux mvpvizweql (nrasapnsqd )
-
01 Jan 2019
(lvlxwncnke) = deemanynch mvpvizweql (nrasapnsqd )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free